Moderna Q2 revenue $4.7B, GAAP EPS $5.24, announces $3B buyback, reiterates ~$21B 2022 sales outlook

Moderna, Inc.

2022-Q2 EPS reported $13.85 revenue$10,815,000,000

Q2 revenue $4.7B vs $4.4B YoY; GAAP net income $2.2B ($5.24 diluted EPS) vs $2.8B ($6.46) YoY.
Board authorizes new $3B share repurchase program; $1.9B used in H1 2022 repurchases.
2022 advance purchase agreements for COVID vaccine expected delivery ~$21B; Q4 sales seen > Q3.
Cost of sales 30% of product sales in Q2, including $499M inventory write-downs and $184M purchase commitment loss.
Four infectious disease vaccines in Phase 3; proof-of-concept data in rare diseases and immuno-oncology expected H2 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.